Business Overview
InspiroGene by McKesson
Guiding and supporting the commercialization of cell and gene therapies.
Bridging the Gap Between Cell and Gene Therapy Innovation and Reality
In the complex world of cell and gene therapy (CGT), inefficiencies in communication, responsiveness and workflow consistency can delay patient access to critical treatments. InspiroGene by McKesson was created to solve these challenges by elevating the therapy experience at every touchpoint.
As an enduring ally, InspiroGene is dedicated to ensuring that patients receive the life-changing treatments they need. Through a thoughtfully designed, configurable approach, InspiroGene streamlines communication, enhances responsiveness and fosters a cohesive, consistent workflow for optimal patient outcomes.
Our Focus Areas
Our suite of services includes:
Advancing Cell and Gene Therapy
InspiroGene by McKesson partners with biopharma to solve the complexities of commercializing cell and gene therapy — combining deep expertise, tailored logistics and a true understanding
of every patient and product journey.
InspiroGene Tech-Enabled Integration
We offer a suite of configurable solutions to support CGT manufacturers from clinical development to full-scale commercialization.
InspiroCare
Our Patient HUB delivers personalized support for patients and data transparency for biopharma partners.
InspiroLink
Our treatment center interface that simplifies CGT ordering, tracking and financial management across all channels.
Key Findings From the 2026 Cell and Gene Therapy Report
The 2026 Cell and Gene Therapy Report examines the opportunities and obstacles shaping patient access today and what healthcare stakeholders must do next to improve it.
~2x
The average number of patients oncologists treat with CGTs has nearly doubled, from 17 to 32 annually, since 2024.1
97%
97% of oncologists now say CGTs could offer some patients the best chance for a cure, up from 93% last year.1
100%
100% of surveyed rheumatologists agree CGTs could offer some patients their best chance at a cure.1
2,198
While 2,198 U.S. sites have participated in CGT trials, just 236 account for half of all trial activity.1
Report
2026 Cell and Gene Report
CGTs are redefining what’s possible in medicine as they continue to move from scientific progress to real-world impact. Now in its third year, the 2026 Cell and Gene Therapy Report examines the opportunities and obstacles shaping patient access today and what healthcare stakeholders must do next to improve it.
Explore InspiroGene by McKesson Stories and Insights
InspiroGene by McKesson Additional Resources
Stay up to date on the latest from InspiroGene by McKesson.
News & Resources
View our curated set of cell and gene therapy publications, podcasts, videos and other resources available for viewing or download.
Cell and Gene Therapy Centers Map
McKesson has developed an interactive map of Qualified Treatment Centers (QTCs) in 109 metropolitan regions across the U.S. as a resource.
Learn More About McKesson’s Solutions
Oncology & Multispecialty Solutions
InspiroGene is working to expand access to cell and gene therapy treatments to improve patient outcomes.
Learn more about how McKesson is advancing oncology and specialty care.
Biopharma Capabilities
InspiroGene brings deep experience to the cell and gene therapy commercialization journey with established solutions to address the complex challenges of bringing these advanced therapies to market.
Learn more about how McKesson is advancing biopharma solutions.
1. Data from the 2026 Cell and Gene Therapy Report, InspiroGene by McKesson